Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders. However, pharmacogenetic studies examining CYP2C19 metabolizer status and es/citalopram treatment outcomes have largely focused on adults. We report a retrospective study of electronic medical record data from 263 youth <19 years of age with anxiety and/or depressive disorders prescribed escitalopram or citalopram and underwent routine clinical CYP2C19 genotyping. Slower CYP2C19 metabolizers experienced more untoward effects than faster metabolizers (p=0.015), including activation symptoms (p=0.029) and had more rapid weight gain (p=0.018). A larger proportion of slower metabolizers discontinued treatment with es/citalopram than normal metabolizers (p=0.007). Meanwhile, faster metabolizers responded more quickly to es/citalopram (p=0.005) and trended toward less time spent in subsequent hospitalizations (p=0.06). These results highlight a disparity in treatment outcomes with es/citalopram treatment in youth with anxiety and/or depressive disorders when standardized dosing strategies were used without consideration of CYP2C19 metabolizer status. Larger, prospective trials are warranted to assess whether tailored dosing of es/citalopram based on CYP2C19 metabolizer status improves treatment outcomes in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Merikangas, K. R., He, J.-P., Burstein, M., Swanson, S. A., Avenevoli, S., Cui, L., Benjet, C., Georgiades, K., & Swendsen, J. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.05.017 · Cited by 6,278
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Common and Costly Hospitalizations for Pediatric Mental Health Disorders
Bardach, N. S., Coker, T. R., Zima, B. T., Murphy, J. M., Knapp, P., Richardson, L. P., Edwall, G., & Mangione-Smith, R. (2014) · Pediatrics · doi:10.1542/peds.2013-3165 · Cited by 227
Emslie, G. J., Ventura, D., Korotzer, A., & Tourkodimitris, S. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181a2b304 · Cited by 210
Strawn, J. R., Welge, J. A., Wehry, A. M., Keeshin, B., & Rynn, M. A. (2015) · Depression and Anxiety · doi:10.1002/da.22329 · Cited by 183
Self-citationStrawn, J. R., Mills, J. A., Sauley, B. A., & Welge, J. A. (2018) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.01.015 · Cited by 98
Self-citationDobson, E. T., Bloch, M. H., & Strawn, J. R. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17r12064 · Cited by 89
Self-citationThe Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression
Findling, R. L., McNamara, N. K., Stansbrey, R. J., Feeny, N. C., Young, C. M., Peric, F. V., & Youngstrom, E. A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.131 · Cited by 64
Cited by
Deng, Y., Zhou, M., Wang, J., Yao, J., Yu, J., Liu, W., Wu, L., Wang, J., & Gao, R. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1869501 · Cited by 362
Walter, H. J., Bukstein, O. G., Abright, A. R., Keable, H., Ramtekkar, U., Ripperger-Suhler, J., & Rockhill, C. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.05.005 · Cited by 335
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Research Review: Pediatric Anxiety Disorders—What Have We Learnt in the Last 10 Years?
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., & Walkup, J. T. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13262 · Cited by 168
Self-citationZobdeh, F., Eremenko, I. I., Akan, M. A., Tarasov, V. V., Chubarev, V. N., Schiöth, H. B., & Mwinyi, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061190 · Cited by 45
“While studies regarding ibuprofen response [37] and aspirin adverse effects [83] only included White subjects, studies on amitriptyline treatment response [94] and escitalopram adverse effects [120] include different ethnicities such as Black Africans, White, and Indian subjects.”
Background
Metadata
- Authors
- Aldrich, S. L., Poweleit, E. A., Prows, C. A., Martin, L. J., Strawn, J. R., & Ramsey, L. B.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-02-19
- Volume
- 10
- Pages
- 99-99
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2915617238
- Cited by
- 120
- References
- 11
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. https://app.cochat.ai/papers/10.3389/fphar.2019.00099
- The paper
- Aldrich, S. L., Poweleit, E. A., Prows, C. A., Martin, L. J., Strawn, J. R., & Ramsey, L. B. (2019). Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.00099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.